Kinevant Sciences

Kinevant Sciences is a clinical-stage biopharmaceutical company dedicated to treating rare autoimmune diseases with significant unmet need. Our lead candidate, namilumab, is an investigational monoclonal antibody being developed for the treatment of sarcoidosis. Namilumab targets GM-CSF, a key pro-inflammatory cytokine and growth factor implicating in the pathogenesis of sarcoidosis and other inflammatory disorders. We plan to initiate a global Phase 2 clinical trial in the first half of 2022 investigating namilumab in pulmonary sarcoidosis, which affects ~90% of all sarcoidosis patients.